What are the advantages of vanzacato/tizakattor/deuterated ivacaftor combination tablets compared with existing CF drugs such as Trikafta?

Trikafta is a CFTR triple therapy that is currently widely used clinically. The combination is elexacaftor, tezacaftor and ivacaftor. The combination of this compound tablet has been improved. vanzacaftor is used to replace elexacaftor, and deutivacaftor is used to replace ivacaftor, which has better pharmacokinetic characteristics. Deuterated ivacaftor replaces hydrogen atoms with deuterium, which can extend the half-life of the drug in the body, thereby achieving a more stable blood concentration and possibly reducing the frequency of medication and side effects. In addition, research shows that this new combination has a lung function improvement effect that is comparable to or even better than that of Trikafta, and is expected to become a new option for the next generation of cystic fibrosis treatment. The specific advantages need to be further evaluated based on future clinical results.